Enanta up 92% as zelicapavir’s RSV journey goes on

Shares in Enanta Pharmaceuticals (Nasdaq: ENTA), a US biotech creating small molecule drugs for viral infections and immunological diseases, closed 92% higher Monday.

The company earlier announced top-line data from RSVHR, a Phase IIb, randomized, double-blind, placebo-controlled study of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or asthma.

Zelicapavir, which received Fast Track designation from the US Food and Drug Administration (FDA), is a novel N-protein inhibitor in development as a once-daily oral treatment for RSV.